Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability.

Abstract:

The development of divinylpyrimidine (DVP) reagents for the synthesis of antibody-drug conjugates (ADCs) with in vivo efficacy and tolerability is reported. Detailed structural characterisation of the synthesised ADCs was first conducted followed by in vitro and in vivo evaluation of the ADCs' ability to safely and selectively eradicate target-positive tumours.

Authors:

SJ Walsh, S Omarjee, FM Dannheim, D-L Couturier, D Bexheti, L Mendil, G Cronshaw, T Fewster, C Gregg, C Brodie, JL Miller, R Houghton, JS Carroll, DR Spring

Journal:

Chem Commun (Camb)

Citation info:

58(12):1962-1965

Publication date:

8th Feb 2022

Full text

DOI